Study: NCT03132129

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed tomography coronary artery calcium scoring
Description: Computed Tomography coronary calcium scoring to assess the presence of subclinical atherosclerosis and allow an estimate of atheroma burden in addition to epicardial adipose tissue characterisation and systolic strain.

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed tomography coronary artery calcium scoring
Description: Computed Tomography coronary calcium scoring to assess the presence of subclinical atherosclerosis and allow an estimate of atheroma burden in addition to epicardial adipose tissue characterisation and systolic strain.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise testing
Description: Physician supervised incremental symptom limited cardiopulmonary exercise tolerance test with ECG and haemodynamic monitoring.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise testing
Description: Physician supervised incremental symptom limited cardiopulmonary exercise tolerance test with ECG and haemodynamic monitoring.

Intervention type: DIAGNOSTIC_TEST
Intervention: Manganese-enhanced magnetic resonance imaging (MEMRI)
Description: A subset of the participants will have cardiac MRI scanning with manganese-based contrast agent, lasting approximately 45-50 minutes. After localisers, baseline functions and native T1 maps have been acquired, Mangafodipir (0.1mL/kg) will be administered intravenously at 1ml/min, with additional T1 maps acquired every 2.5 min after administration of the contrast agent for up to 30 minutes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Manganese-enhanced magnetic resonance imaging (MEMRI)
Description: A subset of the participants will have cardiac MRI scanning with manganese-based contrast agent, lasting approximately 45-50 minutes. After localisers, baseline functions and native T1 maps have been acquired, Mangafodipir (0.1mL/kg) will be administered intravenously at 1ml/min, with additional T1 maps acquired every 2.5 min after administration of the contrast agent for up to 30 minutes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ambulatory blood pressure monitoring
Description: A 24-hour blood pressure monitor will be worn at the end of the visit to the following day.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ambulatory blood pressure monitoring
Description: A 24-hour blood pressure monitor will be worn at the end of the visit to the following day.

Intervention type: DIAGNOSTIC_TEST
Intervention: Accelerometer watch
Description: Watch worn to collect free living physical activity data for 7 days.

Intervention type: DIAGNOSTIC_TEST
Intervention: Accelerometer watch
Description: Watch worn to collect free living physical activity data for 7 days.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: Collection of blood samples from each participant to characterise the participant's health status and to develop a proteomic signature of early heart failure.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: Collection of blood samples from each participant to characterise the participant's health status and to develop a proteomic signature of early heart failure.